Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Historic Asset Writedowns and Impairment for Celldex Therapeutics (CLDX) over the last 5 years, with Q3 2021 value amounting to $3.5 million.

  • Celldex Therapeutics' Asset Writedowns and Impairment changed N/A to $3.5 million in Q3 2021 from the same period last year, while for Dec 2021 it was $18.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.5 million for FY2021, which is 8055.56% down from last year.
  • As of Q3 2021, Celldex Therapeutics' Asset Writedowns and Impairment stood at $3.5 million.
  • In the past 5 years, Celldex Therapeutics' Asset Writedowns and Impairment ranged from a high of $18.7 million in Q1 2018 and a low of $1.8 million during Q1 2019
  • In the last 5 years, Celldex Therapeutics' Asset Writedowns and Impairment had a median value of $8.2 million in 2017 and averaged $9.2 million.
  • The largest annual percentage gain for Celldex Therapeutics' Asset Writedowns and Impairment in the last 5 years was 9036.25% (2019), contrasted with its biggest fall of 9036.25% (2019).
  • Over the past 5 years, Celldex Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $13.0 million in 2017, then soared by 43.67% to $18.7 million in 2018, then tumbled by 90.36% to $1.8 million in 2019, then soared by 705.56% to $14.5 million in 2020, then tumbled by 75.86% to $3.5 million in 2021.
  • Its Asset Writedowns and Impairment stands at $3.5 million for Q3 2021, versus $14.5 million for Q4 2020 and $3.5 million for Q2 2020.